Oophorectomy Linked to Better Survival in BRCA1 Breast Cancer

This article originally appeared here.
Share this content:
Oophorectomy Linked to Better Survival in <i>BRCA1</i> Breast Cancer
Oophorectomy Linked to Better Survival in BRCA1 Breast Cancer

THURSDAY, April 23, 2015 (HealthDay News) -- Oophorectomy is associated with a decrease in mortality in women with breast cancer and a BRCA1 mutation, and women with estrogen receptor-negative breast cancer and a BRCA1 mutation should undergo the procedure shortly after diagnosis, according to research published online April 23 in JAMA Oncology.

Researchers followed 676 women who had early-stage breast cancers and were carriers of BRCA1 or BRCA2 mutations. The women had received treatment for breast cancer, including mastectomy and lumpectomy. Roughly half had undergone an oophorectomy.

Overall, 77.4 percent of women survived over the 20-year follow-up from time of diagnosis, the findings showed. In women who underwent oophorectomy, the adjusted hazard ratio for breast cancer-specific mortality was 0.38 (95 percent confidence [CI], 0.19 to 0.77; P = 0.007) for BRCA1 carriers and 0.57 (95 percent CI, 0.23 to 1.43; P = 0.23) for BRCA2 carriers. For women with estrogen receptor-positive breast cancer, the hazard ratio for breast cancer-specific mortality was 0.76 (95 percent CI, 0.32 to 1.78; P = 0.53), and for women with estrogen receptor-negative breast cancer, the hazard ratio was 0.07 (95 percent CI, 0.01 to 0.51; P = 0.009).

On average, oophorectomy was done six years after the breast cancer diagnosis, but earlier oophorectomy conferred a greater reduction in breast cancer death risk. The protective effect of oophorectomy was especially strong if women had estrogen receptor-negative breast cancer after age 50.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »